SOLEUS CAPITAL MASTER FUND, L.P. 13D and 13G filings for Rigel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-02 09:56 am Purchase | 2023-12-31 | 13G | Rigel Pharmaceuticals, Inc. RIGL | SOLEUS CAPITAL MASTER FUND, L.P. | 944,258 5.400% | 21,956 (+2.38%) | Filing |
| 2023-02-22 4:03 pm Purchase | 2023-02-21 | 13G | Rigel Pharmaceuticals, Inc. RIGL | SOLEUS CAPITAL MASTER FUND, L.P. | 922,302 5.300% | 922,302 (New Position) | Filing |